Physician profile
Kenneth Kleinman
NPI 1689605941
$6,200.58
in general payments reported to CMS, 2019-2025
51 companies · $450 in 2025
The $450 reported for 2025 was more than what 77% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $375 · 2020: $751 · 2021: $2,250 · 2022: $688 · 2023: $984 · 2024: $703 · 2025: $450.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,086 · Education: $50.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,086.16 |
| Education | $50.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $1,222.19 | 2021 | |
| Glaxosmithkline, LLC. | $508.77 | 2020-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Currax Pharmaceuticals LLC | $386.78 | 2021-2024 | Contrave, Nexletol, Onzetra Xsail |
| Pfizer INC. | $307.46 | 2019-2025 | |
| Opko Pharmaceuticals, LLC | $287.66 | 2021-2025 | Rayaldee |
| Amgen INC. | $277.63 | 2019-2024 | Evenity, Tavneos, Otezla |
| Kowa Pharmaceuticals America, INC. | $253.80 | 2020-2022 | |
| Novo Nordisk INC | $235.35 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $230.82 | 2020-2025 | Verquvo, Gardasil 9, Capvaxive |
| Otsuka America Pharmaceutical, INC. | $224.67 | 2019-2024 | Jynarque, Rexulti |
| Mylan Specialty L.P. | $219.80 | 2020-2024 | Yupelri |
| Astrazeneca Pharmaceuticals LP | $196.66 | 2019-2025 | Breztri, Farxiga |
| Novartis Pharmaceuticals Corporation | $183.42 | 2021-2025 | |
| Lilly USA, LLC | $162.93 | 2022-2025 | Mounjaro, Zepbound |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $150.89 | 2019-2021 |
Show all 48 companies
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kenneth Kleinman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.